经动脉灌注吉西他滨和5-氟尿嘧啶联合热疗治疗中晚期胰腺癌的临床分析

目的：探讨经动脉灌注吉西他滨（Gemcitabine，商品名健择）和5-氟尿嘧啶（5-FU）联合内生场热疗治疗中晚期胰腺癌的临床疗效。方法：18例中晚期胰腺癌患者，采用改良Seldinger技术，动脉插管后选择性置管于胰腺癌的供血动脉，灌注吉西他滨1000mg／m^2；之后行内生场热疗，热疗同时经动脉留置导管灌注卡铂400mg／m^2；热疗后，用输液泵经动脉留置管灌注5-FU 1g，连用2d。随访观察客观疗效、临床受益反应、患者的生存期及不良反应等。结果：18例患者的客观缓解率为22．20％，临床受益反应为44．40％，Kaplan-Meier法计算6、9和12个月的累积生存率分别为83．33％、66．67％和33．33％，频数分布法计算中位生存期为11个月。结论：经动脉灌注吉西他滨和5-FU联合内生场热疗治疗中晚期胰腺癌可获得较好的临床疗效，患者耐受良好，值得进一步研究。

Clinical study on transarterial infusion chemotherapy with gemcitabine and 5-fluorouracil combined with endogenetic field tumor hyperthermia in treatment of patients with advanced pancreatic carcinoma

OBJECTIVE: To evaluate the effects and complications of transarterial infusion chemotherapy with gemcitabine and 5-fluorouracil combined with endogenetic field tumor hyperthermia (EFTH) in the treatment of patients with advanced pancreatic carcinoma. METHODS: Eigtheen patients with advanced pancreatic carcinoma received chemotherapy with gemcitabine (1 000 mg/m2) before EFTH by seldinger methods. At the sametime of EFTH carboplatin was used (400 mg/m2). After EFTH 5-fluorouarcil (1 g) was used for 2 days continuously. Gemcitabine and 5-fluorouracil was administered to patients via an interarterialcatheter. Then the tumor response and clinical benefit response were observed. RESULTS: The tumor response rate was 22.20%. A clinical benefit was obtained in 8 cases (44.40%). The 6, 9 and 12 month survival rate of the group were 83.33%, 66.67% and 33.33%, median survival for all the patients was 11 months. CONCLUSIONS: Transarterial infusion chemotherapy with gemcitabine and 5-fluorouracil combined with endogenetic field tumor hyperthermia is a moderatedly active treatment with tolerable side effects. It has definite response rate and also significantly improves the quantity of life of the patients. Its treatment value is worthy of further studying.